Immunotherapeutic and antitumour potential of thalidomide analogues

Bibliography

• FULLERTON PM, KREMER M: Neuropathy after intake of thalidomide. BMJ (1961) 2:855–858.
   PubMed Web of Science ®Google Scholar
• MC BRIDE WG: Thalidomide and congenital abnormalities. Lancet (1961) ii:1358.
   Google Scholar
• MARRIOTT JB, MULLER G, DALGLEISH AG: Thalidomide as an emerging immunotherapeutic agent. Immunol Today (1999) 583:538–540.
   Google Scholar
• •Review of thalidomide's immunomodulatory properties highlighting the remarkable resurgence in its clinical use.
   Google Scholar
• RAJE N, ANDERSON K: Thalidomide- a revival story. N Engl. J. Med. (1999) 341:1606–1609.
   PubMed Web of Science ®Google Scholar
• HALES B: Thalidomide on the comeback trail. Nature Med. (1999) 5:489–490.
   PubMed Web of Science ®Google Scholar
• SHESKIN J: Further observation with thalidomide in lepra reactions Lepr. Rev (1965) 36:183–187.
   Google Scholar
• IYER GCS, LANGUILLON J, RAMANUJAM K etal.: WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull. WHO (1971) 45:719–732.
   Google Scholar
• SAMPAIO EP, KAPLAN G, MIRANDA A et al: The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J. Infect. Dis. (1993) 168:408–414.
   PubMed Web of Science ®Google Scholar
• VOSELSANG GB, FARMER ER, HESS AD et al: Thalidomide for the treatment of chronic graft- versus-host disease N Engl. J. Med. (1992) 326:1055–1058.
   Google Scholar
• SCHULER U, EHNINGER G: Thalidomide: rationale for renewed use in immunological disorders. Dug Safety (1995) 12:364–369.
   PubMed Web of Science ®Google Scholar
• KLAUSNER JD, MAKONKAWKEYOONS, AKARASEWI P et al: The effect of thalidomide on the pathogenesis of human immunodeficiency virus Type 1 and M. tuberculosis infection. J. AIDS (1996) 11:247–257.
   Google Scholar
• HAMURYUDAN V, MAT C, SAIP S et al: Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (1998) 128:443–450.
   PubMed Web of Science ®Google Scholar
• WETTSTEIN AR, MEAGHER AP: Thalidomide in Crohn's disease. Lancet (1997) 350:1445–1446.
   PubMed Web of Science ®Google Scholar
• VASILIAUSKAS EA, KAM LY, ABREU-MARTIN MT et al:An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology (1999) 117:1278–1287.
   PubMed Web of Science ®Google Scholar
• EHRENPREIS ED, KANE SV, COHEN LB, COHEN RD, HANAUER SB. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology (1999) 117:1271–1277.
   Google Scholar
• YOULE M, CLARBOUR J, FURTHING C et al.: Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. BMJ (1989) 298:432.
   PubMed Web of Science ®Google Scholar
• JACOBSON JM, GREENSPAN JS, SPRITZLER J et al.: Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl. J. Med. (1997) 336:1487–1493.
   PubMed Web of Science ®Google Scholar
• ALEXANDER LN, WILCOX CM: A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers. AIDS Res. Hum. Retroviruses (1997) 13:301–304.
   PubMed Web of Science ®Google Scholar
• SHARPSTONE D, ROWBOTTOM A, NELSON M, GAZZARD B: The treatment of microsporidial diarrhoea with thalidomide. AIDS (1995) 9:658–659.
   PubMed Web of Science ®Google Scholar
• REYES-TERÁN G, SIERRA-MADERO JG,MARTINEZ DEL CERRO V et al: Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS (1996) 10:1501–1507.
   PubMed Web of Science ®Google Scholar
• FIFE K, HOWARD MR, GRACIE F et al: Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int. J. STD. AIDS (1998) 9:751–755.
   PubMed Web of Science ®Google Scholar
• SINGHAL S, MEHTA J, DESIKAN R et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl. J. Med. (1999) 18(341):1565–1571.
   Google Scholar
• ••Report demonstrating marked and durableresponses induced by thalidomide in the treatment of patients with refractory multiple myeloma.
   Google Scholar
• JULIUSSON G, CELSING F, TURESSON I et al: Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br j Haematol (2000) 109:89–96.
   PubMed Web of Science ®Google Scholar
• ZOMAS A, ANAGNOSTOPOULOS N, DIMOPOULOS MA: Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent. Bone Marrow Transplant. (2000) 25:1319–1320.
   PubMed Web of Science ®Google Scholar
• HIDESHIMA T, CHAUHAN D, SHIMA Y et al.: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood(2000) 96:2943–2950.
   PubMed Web of Science ®Google Scholar
• •Paper showing the induction of growth arrest of chemoresistant myeloma cell lines and patient myeloma cells by IMiD analogues.
   Google Scholar
• EISEN T, BOSHOFF C, MAK I etal.: Continuous low dose thalidomide: a Phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br j Cancer (2000) 82:812–817.
   Google Scholar
• FINE HA, FIGG WD, JAECKLE K et al: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. I Clin. Ducal (2000) 18:708–715.
   Google Scholar
• PATT YZ, HASSAN MM, LOZANO RD et al.: Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am. j Clin. Oricol (2000) 23:319–321.
   PubMed Web of Science ®Google Scholar
• GUTHEIL J, FINUCANE D: Thalidomide therapy in refractory solid tumour patients. Br. j Haematol (2000) 110:754.
   PubMed Web of Science ®Google Scholar
• ZELDIS JB, WILLIAMS BA, THOMAS SD, ELSAYED ME: STEPS: a comprehensive program for controlling and monitoring access to thalidomide. Clin. Ther. (1999) 21:319–330.
   PubMed Web of Science ®Google Scholar
• SAMPAIO EP, SARNO EN, GALILLY R etal.: Thalidomide selectively inhibits tumour necrosis factor a production by stimulated human monocytes. J. Exp. Med. (1991) 173:699–703.
   Google Scholar
• •Important paper indicating that thalidomide inhibits TNF-a inhibition production by stimulated monocytes and opening up a rationale for clinical use in the treatment of TNF-a mediated disease.
   Google Scholar
• MARRIOTT JB, WESTBY M, DALGLEISH AG: The therapeutic potential of TNF-a inhibitors old and new. Drug Discov. Today (1997) 2:273–282.
   Web of Science ®Google Scholar
• EIGLER A, SINHA B, HARTMANN G,ENDRES S: Taming TNF: strategies to restrain this proinflammatory cytokine. Immuriol Today (1997) 18:487–492.
   PubMedGoogle Scholar
• D'AMATO RJ, LOUGHNAN MS, FLYNN E, FOLKMAN J: Thalidomide is an inhibitor of angiogenesis. Proc. Nati Acad. Sci. USA (1994) 91:4082–4085.
   PubMed Web of Science ®Google Scholar
• •First report showing that thalidomide is anti-angiogenic and opening up clinical use in the treatment of various cancers.
   Google Scholar
• 013YRNE KJ, DALGLEISH AG, BROWNING MJ et al.: The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur. Cancer (2000) 36:151–169.
   Google Scholar
• RUEGG C, YILMAZ A, BIELER G et al: Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nature Med. (1998) 4:408–414.
   PubMed Web of Science ®Google Scholar
• MC HUGH SM, RIFKIN IR, DEIGHTON J et al: The immunosuppressive drug thalidomide induces T helper cell Type 2 (Th2) and concomitantly inhibits Thl cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin. Esp. Immuriol. (1995) 99:160–167.
   PubMed Web of Science ®Google Scholar
• MOLLER DR, WYSOCKA M, GREENLEE BM et al: Inhibition of IL-12 production by thalidomide. I Immuriol (1997) 159:5157–5161.
   Google Scholar
• HASLETT PA, CORRAL LG, ALBERT M, KAPLAN G: Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. I Exp. Med. (1998) 187:1885–1892.
   PubMed Web of Science ®Google Scholar
• ••First report of thalidomide induced T-cellco-stimulation helping to explain some unexpected clinical observations.
   Google Scholar
• WNENDT S, ZWINGENBERGER K: Thalidomide's chirality Nature [letter] (1997) 385:303–304.
   PubMed Web of Science ®Google Scholar
• ERIKSSON T, BJORKMAN S, ROTH B et al: Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality (1995) 7:44–52.
   PubMed Web of Science ®Google Scholar
• MULLER GW, CORRAL LG, SHIRE MG et al: Structural modifications of thalidomide produce analogs with enhanced tumour necrosis factor inhibitory activity. Med. Chem. (1996) 39:3238–3240.
   Web of Science ®Google Scholar
• •Report demonstrating the synthesis of novel TNF-a inhibitors by structural modification of thalidomide.
   Google Scholar
• CORRAL LG, MULLER GW, MOREIRA AL et al.: Selection of novel analogs of thalidomide with enhanced tumour necrosis factor alpha inhibitory activity. Molecular Med. (1996) 2:506–515.
   PubMed Web of Science ®Google Scholar
• MULLER GW, SHIRE MG, WONG LM etal.: Thalidomide analogs and PDE4 inhibition. Bioorg. Med. Chem. Lett. (1998) 8:2669–2674.
   Google Scholar
• MULLER GW, CHEN R, HUANG SY et al.: Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg. Med. Chem. Lett. (1999) 9:1625–1630.
   PubMed Web of Science ®Google Scholar
• CORRAL LG, HASLETT PA, MULLER GW et al:Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-a. j Immuriol (1999) 163:380–386.
   Google Scholar
• ••First report highlighting the distinctionbetween IMiD and SeICID analogues.
   Google Scholar
• OLIVER SJ, CHENG BANQUERIGO ML, BRAHN E: The effect of thalidomide and 2 analogs on collagen induced arthritis. I Rheumatol (1998) 25:964–969.
   Web of Science ®Google Scholar
• MULLER GW, CHEN R, HUANG SY et al.: Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg. Med. Chem. Lett. (1999) 9:1625–1630.
   PubMed Web of Science ®Google Scholar
• CORRAL LG, KAPLAN G: Immunomodulation by thalidomide and thalidomide analogues. Ann. Rheum. Dis. (1999) 58(Suppl. I):1107–1113.
   Google Scholar
• MOREIRA AL, CORRAL LG, YE WG et al.: Thalidomide and thalidomide analogs reduce HIV Type 1 replication in human macrophages in vitro. AIDS Res. Hum. Retrovir: (1997) 13:857–863.
   Google Scholar
• MARRIOTT JB, WESTBY M, COOKSON S et al: CC-3052: a water soluble analog of thalidomide and potent inhibitor of activation-induced TNF-a production. j Immunol (1998) 161:4236–4243.
   PubMed Web of Science ®Google Scholar
• •First in depth characterisation of a thalidomide analogue highlighting the improved activity and water solubility of this SelCID compound.
   Google Scholar
• LA MAESTRA L, ZANINONI A, MARRIOTT JB etal.: The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro. Clin. Exp. kmauriol. (2000) 119:123–129.
   Google Scholar
• SCHEFFLER MR, OLIVER SD, ALLEN E, THOMAS SD: The safety, tolerability and pharmacokinetics of CDC-801, a novel TNF-alpha inhibitor, given as single oral doses, 50 mg to 1 g. American Association of Pharmaceutical Scientists, New Orleans Meeting, November 1999.
   Google Scholar
• TEO S, OLIVER S, HARRIS J et al.: Pharmacokinetics of the thalidomide analogue CC-1088 after multiple oral dose in healthy male subjects. American Association of Pharmaceutical Scientists, New Orleans Meeting November 1999.
   Google Scholar